Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, PF can be grouped into several types.
Idiopathic pulmonary fibrosis, or IPF, is the most common form of the disease, estimated to affect one in every 5,000 people worldwide. In IPF, the underlying cause of fibrosis is not clear, hence the designation “idiopathic,” which means “of unknown cause.”
Like other forms of PF, IPF is a progressive disease, which means that symptoms are milder at the disease’s start and gradually become more severe with time.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.
